HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ocak, S. Articles by Massion, P. P. Search for Related Content PubMed PubMed Citation Articles by Ocak, S. Articles by Massion, P. P.

Mass Spectrometry–based Proteomic Profiling of Lung Cancer

¹ Division of Allergy, Pulmonary and Critical Care Medicine, Thoracic Oncology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; ² Mass Spectrometry Research Center, Department of Biochemistry, Vanderbilt University Medical Center, Nashville, Tennessee; and ³ Veterans Affairs Medical Center, Nashville, Tennessee

Correspondence and requests for reprints should be addressed to Pierre P. Massion, M.D., Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Preston Research Building 640, Nashville TN 37232-6838. E-mail: pierre.massion{at}vanderbilt.edu

ABSTRACT

In an effort to further our understanding of lung cancer biology and to identify new candidate biomarkers to be used in the management of lung cancer, we need to probe these tissues and biological fluids with tools that address the biology of lung cancer directly at the protein level. Proteins are responsible of the function and phenotype of cells. Cancer cells express proteins that distinguish them from normal cells. Proteomics is defined as the study of the proteome, the complete set of proteins produced by a species, using the technologies of large-scale protein separation and identification. As a result, new technologies are being developed to allow the rapid and systematic analysis of thousands of proteins. The analytical advantages of mass spectrometry (MS), including sensitivity and high-throughput, promise to make it a mainstay of novel biomarker discovery to differentiate cancer from normal cells and to predict individuals likely to develop or recur with lung cancer. In this review, we summarize the progress made in clinical proteomics as it applies to the management of lung cancer. We will focus our discussion on how MS approaches may advance the areas of early detection, response to therapy, and prognostic evaluation.

Key Words: proteome • translational research • biomarkers